Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Intracellular Target Access The compound was able to enter the cell models used in the foundational study and reduce the intracellular target-engagement marker 1-methylnicotinamide
Its for people with mild neuropathy
Thymosin Beta-4 Heritage: Parent compound is endogenous and well-characterized Clinical Trials: RegeneRx trials showed generally favorable safety in ophthalmic and cardiac applications Cancer Concerns: Theoretical concerns about cell migration and tumor potential
Bulk orders automatically save 20% on any 10+ vials (BAC excluded) Important Notice: This product is sold strictly for laboratory research purposes only
I missed a daily dose Community protocols generally do not double up after a missed dose
US$ 24.54
US$ 29.87
US$ 28.23
US$ 20.70
US$ 29.41
US$ 25.27
US$ 20.44
